Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy

Abstract Small cell lung cancer (SCLC) patients frequently experience a remarkable response to first-line therapy. Follow up maintenance treatments aim to control residual tumor cells, but generally fail due to cross-resistance, inefficient targeting of tumor vulnerabilities, or dose-limiting toxici...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jana Samarin, Hana Nůsková, Piotr Fabrowski, Mona Malz, Eberhard Amtmann, Minerva J. Taeubert, Daniel Pastor-Flores, Daniel Kazdal, Roman Kurilov, Nicole de Vries, Hannelore Pink, Franziska Deis, Johanna Hummel-Eisenbeiss, Lisa Renz, Kamini Kaushal, Michael Morgen, Tobias P. Dick, Gerhard Hamilton, Martina Muckenthaler, Moritz Mall, Bryce Lim, Taishi Kanamaru, Glynis Klinke, Martin L. Sos, Julia Frede, Aubry K. Miller, Hamed Alborzinia, Nikolas Gunkel
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-04-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-026-71608-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!